Sobi welcomes the European Commissions initiative on cardiovascular health checks, particularly its recognition that kidney health is a core part of cardiovascular prevention. This reflects the strong cardio-renal-metabolic connection: kidney disease significantly increases the risk of hypertension, heart failure, stroke, arrhythmias, and cardiovascular mortality, even at early stages.
SOB
Sobi
Company · Sweden · EU Transparency Register 232923831740-31
2
positions filed
in the 665 files tracked
2
legislative files
of 665 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #751 by legislative files engaged, a count of participation, not a measure of influence.
0.8
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2018
in the register since
Declares membership of
- Sobi is member of EUCOPE
- https://www.eucope.org/members/
- Sobi is a member of the European Business Summits https://ebsummits.eu/
- Sobi is a member of EKHA https://ekha.eu/supporters/
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Swedish Orphan Biovitrum (Sobi)
- Head office
- Stockholm, Sweden
- EU office
- Zaventem
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Sobi in PolicySpeak: request access →
Work at Sobi? so we know who speaks for it.
Their record over time
Sobi filed 2 positions between 5 Jan 2021 and 18 May 2026, across 2 of the 665 legislative files tracked here, attaching a full position paper 1 time.
2021 · 1 filed2026 · 1 filed
What they argued
Sobi is a Swedish based international biopharmaceutical company focused on rare diseases (RDs), mostly within Haematology and Immunology. We are dedicated to researching and providing sustainable access to innovative treatments that transform the lives of people with RDs.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Sobi next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 12.
Is this your organization?
Everything on this page comes from Sobi’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.